Patents by Inventor Mark E. Fraley

Mark E. Fraley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tyrosine kinase inhibitors
    Patent number: 6420382
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: July 16, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, George D. Hartman, Randall W. Hungate
  • Orally active salts with tyrosine kinase activity
    Publication number: 20020072526
    Abstract: The present invention relates to orally active salts of compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: October 17, 2001
    Publication date: June 13, 2002
    Inventors: Mark E. Fraley, Shyam B. Karki, Yuntae Kim
  • Angiogenesis inhibitors
    Patent number: 6380203
    Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Fraley, Randall W. Hungate, Richard L. Kendall, Ruth Rutledge, Kenneth A. Thomas, Jr., Robert Rubino
  • Tyrosine kinase inhibitors
    Publication number: 20010047007
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 20, 2001
    Publication date: November 29, 2001
    Inventors: Mark E. Fraley, George D. Hartman, Randall W. Hungate
  • Tyrosine kinase inhibitors
    Publication number: 20010044451
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 20, 2001
    Publication date: November 22, 2001
    Inventors: Mark E. Fraley, George D. Hartman, Randall W. Hungate
  • Tyrosine kinase inhibitors
    Patent number: 6313138
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: November 6, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, George D. Hartman, Randall W. Hartman
  • Tyrosine kinase inhibitors
    Patent number: 6306874
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: October 23, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
  • Angiogenesis inhibitors
    Patent number: 6265403
    Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases and conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy, and the like in mammals.
    Type: Grant
    Filed: January 7, 2000
    Date of Patent: July 24, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Randall W. Hungate, Andrew J. Tebben
  • Tyrosine kinase inhibitors
    Patent number: 6245759
    Abstract: The present invention relates to pyrazolo-pyrimidinyl compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: June 12, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Fraley, Randall W. Hungate
  • Angiogenesis inhibitors
    Patent number: 6235741
    Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: May 22, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Randall W. Hungate, Richard L. Kendall, Ruth Rutledge, Kenneth A. Thomas, Jr., Robert Rubino, Mark E. Fraley
  • Angiogenesis inhibitors
    Patent number: 6228871
    Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases and conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.
    Type: Grant
    Filed: June 29, 1999
    Date of Patent: May 8, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Randall W. Hungate, William F. Hoffman, William R. Huckle, Richard L. Kendall, Kenneth A. Thomas, Jr.
  • Thrombin inhibitors
    Patent number: 5872138
    Abstract: A compound which inhibits human thrombin and which has the general structure ##STR1##
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: February 16, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Adel M. Naylor-Olsen, Gerald S. Ponticello, Joseph P. Vacca, Randall W. Hungate, Craig Coburn, Brian T. Phillips, S. D. Lewis, Mark E. Fraley
  • HIV protease inhibitors useful for the treatment of AIDS
    Patent number: 5846978
    Abstract: Compounds such as ##STR1## or pharmaceutically acceptable salts thereof, are HIV protease inhibitors. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: December 8, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Craig A. Coburn, Mark E. Fraley, M. Katharine Holloway, Randall W. Hungate, Kristine Prendergast
  • Thrombin inhibitors
    Patent number: 5792761
    Abstract: A compound which inhibits human thrombin and where has the structure ##STR1##
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: August 11, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Adel M. Naylor-Olsen, Randall W. Hungate, Joseph P. Vacca
  • Pyridinone thrombin inhibitors
    Patent number: 5744486
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and have the following structure: ##STR1## for example: ##STR2##
    Type: Grant
    Filed: March 31, 1997
    Date of Patent: April 28, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Philip E. Sanderson, Adel M. Naylor-Olsen, Dona L. Dyer, Joseph P. Vacca, Richard C. A. Isaacs, Bruce D. Dorsey, Mark E. Fraley
  • Pyridinone thrombin inhibitors
    Patent number: 5668289
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and have the following structure: ##STR1## for example: ##STR2##
    Type: Grant
    Filed: June 24, 1996
    Date of Patent: September 16, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Philip E. Sanderson, Adel M. Naylor-Olsen, Dona L. Dyer, Joseph P. Vacca, Richard C. A. Isaacs, Bruce D. Dorsey, Mark E. Fraley